ClinicalTrials.gg

Program

MT1013

A development code. Also written as “[14C] MT1013/MT1013 Injection”, “Single ascending doses of MT1013” and “Multiple ascending doses of MT1013”.

Its studies are mostly in Hyperparathyroidism, Secondary, led by 2 companies.

Furthest: phase 3, since Aug 1, 20256 company-led studies, 2 open or runningNext primary completion: Nov 26, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shaanxi Micot Pharmaceutical Technology41 open or runningphase 3since Aug 1, 2025Nov 13, 2024Nov 26, 2026phase 3 · NCT07122401
Shaanxi Micot Technology21 open or runningphase 2since May 8, 2025Feb 20, 2021none ahead

Also a collaborator on its studies: wcct-global.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2021First study: phase 1 study in Healthy VolunteerNew to Shaanxi Micot TechnologyShaanxi Micot Technology · NCT04783090 · 40 enrolled · United States
  2. Nov 13, 2024Shaanxi Micot Pharmaceutical Technology's first study: phase 2 study in Hyperparathyroidism, SecondaryNew to Shaanxi Micot Pharmaceutical TechnologyShaanxi Micot Pharmaceutical Technology · NCT06690242 · 115 enrolled · China
  3. Dec 18, 2024Phase 2 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT06747247 · 98 enrolled · China
  4. May 8, 2025Phase 2 study in Hyperparathyroidism, SecondaryShaanxi Micot Technology · NCT06976177 · 310 planned · China
  5. Aug 1, 2025Phase 3 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT07122401 · 424 planned · China
  6. Nov 23, 2025Phase 1 study in Hemodialysis Subjects With Secondary HyperparathyroidismShaanxi Micot Pharmaceutical Technology · NCT07284043 · 6 enrolled · China

Ahead

  1. Nov 26, 2026Primary completion: phase 3 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT07122401

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07284043Hemodialysis Subjects With Secondary Hyperparathyroidism · China1CompletedShaanxi Micot Pharmaceutical TechnologyMay 14, 20266
NCT07122401Hyperparathyroidism, Secondary · China3RecruitingShaanxi Micot Pharmaceutical TechnologyNov 26, 2026424
NCT06976177Hyperparathyroidism, Secondary · China2RecruitingShaanxi Micot TechnologyAug 19, 2025310
NCT06747247Hyperparathyroidism, Secondary · China2CompletedShaanxi Micot Pharmaceutical TechnologyMay 12, 202598
NCT06690242Hyperparathyroidism, Secondary · China2CompletedShaanxi Micot Pharmaceutical TechnologyAug 30, 2025115
NCT04783090Healthy Volunteer · United States1CompletedShaanxi Micot TechnologyDec 31, 202140

How it is read

Names in the registry

  • “MT1013”, 5 entries
  • “[14C] MT1013/MT1013 Injection”, 2 entries
  • “Single ascending doses of MT1013”, 1 entry
  • “Multiple ascending doses of MT1013”, 1 entry

Codes read as this program: MT1013.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.